Chemomab Therapeutics Earnings Estimate

CMMB Stock  USD 1.45  0.18  11.04%   
By analyzing Chemomab Therapeutics' earnings estimates, investors can diagnose different trends across Chemomab Therapeutics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Chemomab Therapeutics Ltd is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
 
Interest Hikes
Chemomab Therapeutics is projected to generate -0.02 in earnings per share on the 31st of December 2025. Chemomab Therapeutics earnings estimates show analyst consensus about projected Chemomab Therapeutics Ltd EPS (Earning Per Share). It derives the highest and the lowest estimates based on Chemomab Therapeutics' historical volatility. Many public companies, such as Chemomab Therapeutics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Chemomab Therapeutics' earnings estimates, investors can diagnose different trends across Chemomab Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes. As of February 6, 2026, Gross Profit is expected to decline to about (64.3 K)Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chemomab Therapeutics Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

Chemomab Therapeutics Earnings per Share Projection vs Actual

About Chemomab Therapeutics Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Chemomab Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Chemomab Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Chemomab Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-92.4 M-97 M
Earnings Yield(0.39)(0.41)
Price Earnings Ratio(2.68)(2.81)
Price Earnings To Growth Ratio 0.04  0.07 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Chemomab Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Chemomab Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Chemomab Therapeutics Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Chemomab Therapeutics Ltd Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chemomab Therapeutics Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.
You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chemomab Therapeutics. Projected growth potential of Chemomab fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Chemomab Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(1.45)
Return On Assets
(0.41)
Return On Equity
(0.73)
Chemomab Therapeutics's market price often diverges from its book value, the accounting figure shown on Chemomab's balance sheet. Smart investors calculate Chemomab Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Chemomab Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Chemomab Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Chemomab Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Chemomab Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.